Skip to main content

Influence of smoking and gender on the disposition kinetics of metoprolol

European Journal of Clinical Pharmacology volume 33, pages 355–361 (1987)Cite this article

Summary

The purpose of this study was to examine the influence of cigarette smoking and gender on the pharmacokinetics of metoprolol.

Eighteen volunteers with no evidence of clinical disease each randomly received the following doses of metoprolol tartrate: 100 mg orally, 200 mg orally and 20 mg as a constant-rate intravenous infusion over 20 min.

The only significant difference between smokers (S) and nonsmokers (NS) was that S had a larger steady-state volume of distribution (3.3 vs 2.5 l/kg). There were no differences in half-life, systemic clearance or bioavailability (f). No differences were observed between males (M) and females (FM) for any of the kinetic parameters examined. Systemic bioavailability varied markedly between subjects (range: 15 to 92%). In fifteen of the eighteen subjects, f was higher after the 200-mg dose compared to the 100-mg dose.

These results suggest that metoprolol may be subject to saturable presystemic elimination and extend the previous observations of Johnsson et al. [1] who showed that f increased from 31% to 46% when doses were increased from 20 to 100 mg. However, the difference in f as the dose is increased is unlikely to be clinically significant since the mean difference is smaller than the variation in f among subjects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Johnsson G, Regardh CG, Sorvell L (1975) Combined pharmacokinetic and pharmacodynamic studies in man of the adrenergic β-receptor antagonist metoprolol. Acta Pharmacol Toxicol 36 [Suppl 5]: 31–44

    Google Scholar 

  2. Jack D, Quarterman C, Zaman R, Kendall M (1982) Variability of beta-blocker pharmacokinetics in young volunteers. Eur J Clin Pharmacol 23: 37–42

    Google Scholar 

  3. Vesell E (1982) On the significance of host factors that affect drug disposition. Clin Pharmacol Ther 31: 1–7

    Google Scholar 

  4. Wilson K (1984) Sex-related differences in drug disposition in man. Clin Pharmacol 9: 189–202

    Google Scholar 

  5. Giudicelli J, Tillement J (1977) Influence of sex on drug kinetics in man. Clin Pharmacokinet 2: 157–166

    Google Scholar 

  6. Proksch R, Lamy P (1977) Sex variation and drug therapy. Drug Intell Clin Pharm 11: 398–406

    Google Scholar 

  7. Kato R (1974) Sex-related differences in drug metabolism. Drug Metab Rev 3: 1–32

    Google Scholar 

  8. Jusko W (1978) Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm 6: 7–39

    Google Scholar 

  9. Jusko W (1979) Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev 9: 221–236

    Google Scholar 

  10. Jusko W (1984) Smoking effects in pharmacokinetics. In: Benet L, Massoud N, Gambertoglio J (eds), Pharmacokinetic basis for drug treatment. Raven Press, New York

    Google Scholar 

  11. Jick H (1974) Smoking and clinical drug effects. Med Clin N Am 58: 1143–1149

    Google Scholar 

  12. US Department of Health, Education and Welfare (1979) Smoking and health: A report of the surgeon general. DHEW Publication No. (PHS) 79-50066, Washington, DC

  13. Dawson G, Vestal R (1982) Smoking and drug metabolism. Pharmacol Ther 15: 207–221

    Google Scholar 

  14. Yamaoka K, Nakagawa T, Uno T (1978) Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558

    Google Scholar 

  15. Benet L, Galeazzi R (1979) Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68: 1071–1074

    Google Scholar 

  16. Perrier D, Mayersohn M (1982) Noncompartmental determination of the steady-state volume of distribution for any mode of administration. J Pharm Sci 71: 372–373

    Google Scholar 

  17. Kim K, Kohout F (1975) Analyses of variance and covariance: Subprograms ANOVA and ONEWAY. In: Nie N, Hull C, Steinbrenner K, Bent D (eds) Statistical package for the social sciences (SPSS). Mc Graw-Hill, New York

    Google Scholar 

  18. Winer B (62) Statistical principles in experimental design. McGraw-Hill, New York, pp 298–378

  19. Jennrich R, Sampson P, Frane J (1981) P2V Analysis of variance and covariance including repeated measures. In: Dixon W, Brown M, Engelman L, Frane J, Hill M, Jennrich R, Toporek J (eds) BMDP statistical software. University of California Press, Berkeley, CA

    Google Scholar 

  20. Lam F, Hung C, Perrier D (1985) Estimation of variance for harmonic mean half-lives. J Pharm Sci 74: 229–231

    Google Scholar 

  21. Wilkinson G, Shand D (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377–390

    Google Scholar 

  22. Regardh C, Borg K, Johansson R, Johnsson G, Palmer L (1974) Pharmacokinetic studies on the selective β1-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm 2: 347–364

    Google Scholar 

  23. Hitzenberger G, Fitscha P, Beveridge T, Nuesch E, Pacha W (1982) Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br J Clin Pharmacol 13: 217S-222S

    Google Scholar 

  24. Vestal R, Wood A, Branch R, Shand D, Wilkinson G (1979) Effects of age and cigarette smoking on the disposition of propranolol in man. Clin Pharmacol Ther 26: 8–15

    Google Scholar 

  25. Gardner S, Cady W, Ong Y (1980) Effect of smoking on the elimination of propranolol hydrochloride. Int J Clin Pharmacol Ther Toxicol 18: 421–424

    Google Scholar 

  26. Barrett A, Collum V (1968) The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias. Br J Pharmacol 34: 43–55

    Google Scholar 

  27. Regardh C, Johnsson G, Jordo L, Lundborg P, Persson B, Ronn O (1980) Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J Cardiovasc Pharmacol 2: 715–723

    Google Scholar 

  28. Parving H (1972) The effect of hypoxia and carbon monoxide exposure on plasma volume and capillary permeability to albumin. Scand J Clin Lab Invest 30: 49–56

    Google Scholar 

  29. Jordo L, Attman P, Aurell M, Johansson L, Johnsson G, Regardh C (1980) Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmakokinet 5: 169–180

    Google Scholar 

  30. Shand D, Rangano R (1972) The disposition of propranolol I: Elimination during oral absorption in man. Pharmacology 7: 159–168

    Google Scholar 

  31. Gomeni R, Bianchetti G, Sega R, Morselli P (1977) Pharmacokinetics of propranolol in normal healthy volunteers. J Pharmacokinet Bipharm 5: 183–192

    Google Scholar 

  32. Mackichan J, Pyszczynski D, Jusko W (1980) Dose-dependent disposition of oral propranolol in normal subjects. Biopharm Drug Dispos 1: 159–166

    Google Scholar 

  33. Wargin W, Sawchuk R, McBride J, McCoy H, Rylander M (1982) Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients. Eur J Drug Metab Pharmacokinet 7: 183–189

    Google Scholar 

  34. Vesell E (1982) On the significance of host factors that affect drug disposition. Clin Pharmacol Ther 31: 1–7

    Google Scholar 

  35. Lennard M, Tucker G, Woods H (1986) The polymorphic oxidation of β-adrenoceptor antagonists. Clinical pharmacokinetic considerations. Clin Pharmacokinet 11: 1–17

    Google Scholar 

  36. Lennard M, Silas J, Freestone S, Ramsay L, Tucker G, Wood H (1982) Oxidation phenotype — a major determinant of metoprolol metabolism and response. N Eng J Med 307: 1558–1560

    Google Scholar 

  37. Lennard M, Silas J, Freestone S, Tucker G, Ramsay L, Woods H (1983) Impaired metabolism of metoprolol in poor hydroxylators of debrisoquine. Drugs 25 [Suppl 2]: 147–148

    Google Scholar 

  38. Lennard M, Tucker G, Silas M, Freestone S, Ramsay L, Woods L (1983) Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers. Clin Pharmacol Ther 34: 732–734

    Google Scholar 

  39. Lennard M, Silas J, Freestone S, Trevethick J (1982) Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. Br J Clin Pharmacol 14: 301–303

    Google Scholar 

  40. Lennard M, Freestone S, Ramsay L, Tucker G, Woods H (1983) Oxidation phenotype and beta-blockers. N Eng J Med 308: 965

    Google Scholar 

  41. Shah R, Oates N, Idle J, Smith R (1982) Beta-blockers and drug oxidation status. Lancet 1: 508–509

    Google Scholar 

  42. Lennard M, Tucker G, Silas J, Woods H (1986) Debrisoquine oxidation phenotype and metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica 15: 435–447

    Google Scholar 

  43. Dayer P, Leemann T, Marmy A, Rosenthaler J (1985) Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behavior of atenolol, bopindolol and metoprolol. Eur J Clin Pharmacol 28: 317–320

    Google Scholar 

  44. McGourty J, Silas J, Lennard M, Tucker G, Woods H (1985) Metoprolol metabolism and debrisoquine polymorphism — population and family studies. Br J Clin Pharmacol 20: 555–566

    Google Scholar 

  45. Briant R, Dorington R, Ferry D, Paxton J (1983) Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine. Eur J Clin Pharmacol 25: 353–356

    Google Scholar 

  46. Kendall M, Brown D, Yates R (1977) Plasma metoprolol concentrations in young, old and hypertensive subjects Br J Clin Pharmacol 4: 497–499

    Google Scholar 

  47. Regardh C, Landahl S, Larsson M, Lundborg P, Steen B, Hoffmann K, Lagerstrom P (1983) Pharmacokinetics of metoprolol and its metabolite α-OH-metoprolol in healthy, non-smoking, elderly individuals. Eur J Clin Pharmacol 24: 221–226

    Google Scholar 

  48. Quarterman C, Kendall M, Jack D (1981) The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol 11: 287–294

    Google Scholar 

  49. Larsson M, Landahl S, Lundbog P, Regardh C (1984) Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment. Eur J Clin Pharmacol 27: 217–222

    Google Scholar 

Download references

Author information

Author notes

  1. L. J. Schaaf

    Present address: College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA

Affiliations

  1. College of Pharmacy, University of Arizona, Tucson, Arizona, USA

    L. J. Schaaf, M. B. Mayersohn & D. G. Perrier

  2. College of Medicine, University of Arizona, Tucson, Arizona, USA

    S. C. Campbell

  3. Veterans Administration Hospital, Tucson, Arizona, USA

    S. C. Campbell & T. Vagedes

  4. Faculty of Pharmacy, University of Toronto, Toronto, Canada

    D. G. Perrier

Authors
  1. L. J. Schaaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. C. Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. B. Mayersohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. Vagedes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. G. Perrier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schaaf, L.J., Campbell, S.C., Mayersohn, M.B. et al. Influence of smoking and gender on the disposition kinetics of metoprolol. Eur J Clin Pharmacol 33, 355–361 (1987). https://doi.org/10.1007/BF00637630

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00637630

Key words

  • metoprolol
  • smoking
  • gender
  • pharmacokinetics
  • HPLC
  • healthy volunteers